Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
innocenza.palaia@uniroma1.it
Innocenza Palaia
Professore Associato
Struttura:
DIPARTIMENTO MATERNO INFANTILE E SCIENZE UROLOGICHE
E-mail:
innocenza.palaia@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Cediranib in ovarian cancer. state of the art and future perspectives
TUMOR BIOLOGY
2016
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials
ONCOTARGET
2016
Type B versus Type C Radical Hysterectomy After Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma: A Propensity-Matched Analysis
ANNALS OF SURGICAL ONCOLOGY
2016
Erythropoiesis-stimulating agents in gynecological malignancies: a study-level meta-analysis
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
2016
Sexual health and quality of life assessment among ovarian cancer patients during chemotherapy
ONCOLOGY
2016
Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer
ANNALS OF SURGICAL ONCOLOGY
2016
Ixabepilone for the treatment of endometrial cancer
EXPERT OPINION ON INVESTIGATIONAL DRUGS
2016
Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
2016
Trabectedin in heavily pretreated recurrent ovarian cancer patients: a case-control study
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2016
Effectiveness of Intraperitoneal Chemotherapy in Recurrent Ovarian Carcinoma: Toxicity, Survival Benefits and Related Quality of Life
JOURNAL OF WOMEN'S HEALTH
2016
Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and meta-analysis
OBSTETRICAL & GYNECOLOGICAL SURVEY
2016
Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis
ONCOTARGET
2016
PARP inhibition: a promising therapeutic target in ovarian cancer
CELLULAR AND MOLECULAR BIOLOGY
2015
Advances in anti-angiogenic agents for ovarian cancer treatment: the role of trebananib (AMG 386)
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
2015
Immunotherapy of ovarian cancer: the role of checkpoint inhibitors
JOURNAL OF IMMUNOLOGY RESEARCH
2015
Bmi is a key prognostic factor in stage iiic-iv ovarian cancer diagnosed prior 65 years old: a 10-year survival analysis
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2015
EVALUATION OF SEXUAL DYSFUNCTIONS DURING CHEMOTHERAPY: PRELIMINARY DATA
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2015
Quality of life and sexual function in cervical cancer patients after type II-III/type B-C radical hysterectomy: what we have to understand on satisfaction and supportive care needs
XXVII Congresso Nazionale SPIGC 2015 (Brescia, 11-13 Giugno 2015)
2015
Secondary cytoreduction in platinum-resistant recurrent ovarian cancer: a single-institution experience
ANNALS OF SURGICAL ONCOLOGY
2015
Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma. Younger and older patients should be equally treated. A prospective study and literature review
GYNECOLOGIC ONCOLOGY
2015
« prima
< precedente
1
2
3
4
5
6
7
8
seguente ›
ultima »
Progetti di Ricerca
Danni collaterali da COVID-19: impatto del ritardo diagnostico-terapeutico in patologie ostetriche e ginecologiche e ruolo della telemedicina.
Il carcinoma ovarico e le terapie oncologiche di fine vita: cronicizzazione della chemioterapia, stop alle terapie convenzionali e cure palliative. Studio EOLO (End Of Life Ovarian cancer)
GESTIONE PREOPERATORIA IN CHIRURGIA OSTETRICA E GINECOLOGICA: DIETA LIBERA VERSUS DIETA PRIVA DI SCORIE. STUDIO CLINICO RANDOMIZZATO
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma